Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTN9D8E)

• DTT Name: Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DTT Info
• Gene Name: GRIN2B

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[1]

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CERC-301	DMSABRI	Major depressive disorder	6A70.3	Phase 2	[2]
CP-101,606	DMIU19E	Parkinson disease	8A00.0	Phase 2	[3]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[4]
MIJ821	DMN45RI	Major depressive disorder	6A70.3	Phase 2	[5]
RGH-896	DMCHZAN	Peripheral neuropathy	8C0Z	Phase 2	[6]
EVT100	DMAKWQD	Major depressive disorder	6A70.3	Phase 1	[7]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[8]
Neu-2000	DMNJTLC	Cardiac arrest	MC82	Phase 1	[9]

14 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EVT-101	DMOYMGV	Neuropathic pain	8E43.0	Discontinued in Phase 2	[10]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[11]
Besonprodil	DMMAFQP	Parkinson disease	8A00.0	Discontinued in Phase 1	[10]
EVT-103	DM9450Z	Major depressive disorder	6A70.3	Discontinued in Phase 1	[12]
DIZOCILPINE	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[13]
L-687414	DM56VPY	N. A.	N. A.	Terminated	[14]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[15]
L-695902	DMT1DNS	N. A.	N. A.	Terminated	[14]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[16]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[14]
L-701324	DMAIJSX	Cerebrovascular ischaemia	8B1Z	Terminated	[16]
MDL-105519	DMHUJCI	N. A.	N. A.	Terminated	[17]
RO-25-6981	DM3H921	Cancer related pain	MG30	Terminated	[18]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[19]

101 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+)-HA966	DMKWEAJ	Discovery agent	N.A.	Investigative	[15]
(D)-Ala-Pro-Glu	DMGXTSB	Discovery agent	N.A.	Investigative	[20]
(R)-2-Amino-5-phosphono-pentanoic acid	DMSY4CK	Discovery agent	N.A.	Investigative	[21]
(R)-2-Amino-7-phosphono-heptanoic acid	DM4XEHR	Discovery agent	N.A.	Investigative	[21]
(RS)-(tetrazol-5-yl)glycine	DMYZCRF	Discovery agent	N.A.	Investigative	[15]
1,3-ditolylguanidine	DM04KS1	Discovery agent	N.A.	Investigative	[22]
2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol	DMFGCS1	Discovery agent	N.A.	Investigative	[23]
2-(4-Phenoxy-benzyl)-1H-benzoimidazole	DM65IF1	Discovery agent	N.A.	Investigative	[24]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	DM3HANW	Discovery agent	N.A.	Investigative	[24]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	DMFO19B	Discovery agent	N.A.	Investigative	[24]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	DMJSBFU	Discovery agent	N.A.	Investigative	[24]
2-Methylamino-succinic acid(NMDA)	DMKP6BM	Discovery agent	N.A.	Investigative	[15]
2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	DM5D09Q	Discovery agent	N.A.	Investigative	[25]
3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one	DMAH4DG	Discovery agent	N.A.	Investigative	[14]
3-Hydroxy-1H-benzo[b]azepine-2,5-dione	DMZSOPU	Discovery agent	N.A.	Investigative	[26]
3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	DMYR350	Discovery agent	N.A.	Investigative	[26]
3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	DMTEJOY	Discovery agent	N.A.	Investigative	[26]
3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	DM7HKIF	Discovery agent	N.A.	Investigative	[26]
3-phenyl-4-hydroxyquinolin-2(1H)-one	DM2C9X8	Discovery agent	N.A.	Investigative	[16]
4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	DMXZ9PI	Discovery agent	N.A.	Investigative	[27]
4,6-Dichloro-1H-indole-2-carboxylic acid	DM62XC3	Discovery agent	N.A.	Investigative	[28]
4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	DMCOJIL	Discovery agent	N.A.	Investigative	[25]
4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	DMQZ0D6	Discovery agent	N.A.	Investigative	[4]
4-Benzyl-1-phenethyl-piperidine hydrochloride	DMAI6X2	Discovery agent	N.A.	Investigative	[29]
4-Bromo-3-hydroxy-1H-quinolin-2-one	DMYOCFX	Discovery agent	N.A.	Investigative	[27]
4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	DM2QJ5A	Discovery agent	N.A.	Investigative	[27]
4-Chloro-3-hydroxy-1H-quinolin-2-one	DMMALY3	Discovery agent	N.A.	Investigative	[27]
4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	DMT3H2X	Discovery agent	N.A.	Investigative	[16]
4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	DM64WSV	Discovery agent	N.A.	Investigative	[29]
4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	DM74G6Q	Discovery agent	N.A.	Investigative	[4]
4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	DML8B3T	Discovery agent	N.A.	Investigative	[29]
4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	DMXLVJW	Discovery agent	N.A.	Investigative	[29]
4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	DM8JM4Q	Discovery agent	N.A.	Investigative	[4]
4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	DM5J7O8	Discovery agent	N.A.	Investigative	[29]
4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	DMLCIJX	Discovery agent	N.A.	Investigative	[29]
4-[3-(4-Phenyl-butylamino)-propyl]-phenol	DMOF9YN	Discovery agent	N.A.	Investigative	[30]
4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	DMKDBHN	Discovery agent	N.A.	Investigative	[29]
4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	DMA21GM	Discovery agent	N.A.	Investigative	[29]
5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	DMUADN4	Discovery agent	N.A.	Investigative	[31]
5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	DMZJKIU	Discovery agent	N.A.	Investigative	[14]
5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	DMG4UCX	Discovery agent	N.A.	Investigative	[14]
6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	DMNEJ8W	Discovery agent	N.A.	Investigative	[31]
6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	DMURJ34	Discovery agent	N.A.	Investigative	[32]
6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	DMZP3XJ	Discovery agent	N.A.	Investigative	[24]
6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	DM84CTA	Discovery agent	N.A.	Investigative	[32]
6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	DMZTXDV	Discovery agent	N.A.	Investigative	[24]
7-chloro-3-hydroxyquinazoline-2,4-dione	DM3OMLU	Discovery agent	N.A.	Investigative	[33]
8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	DMPVU7H	Discovery agent	N.A.	Investigative	[26]
8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	DM842L6	Discovery agent	N.A.	Investigative	[26]
8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	DMY8W0K	Discovery agent	N.A.	Investigative	[26]
8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	DMBZSAO	Discovery agent	N.A.	Investigative	[26]
Ala-Pro-Glu	DMTWB54	Discovery agent	N.A.	Investigative	[20]
AP-7	DMBU942	Discovery agent	N.A.	Investigative	[34]
Benzyl 4-aminobutyl(3-aminopropyl)carbamate	DMOKVAT	Discovery agent	N.A.	Investigative	[35]
CGP61594	DM8KFZH	Discovery agent	N.A.	Investigative	[15]
CN-2097	DMJA8I4	Neurological disorder	6B60	Investigative	[15]
Conantokin-G	DMC2IYH	Discovery agent	N.A.	Investigative	[36]
Conantokin-R	DMN4KJI	Discovery agent	N.A.	Investigative	[36]
Conantokins G	DMLHF3E	Discovery agent	N.A.	Investigative	[37]
Conantokins T	DMV6H5S	Discovery agent	N.A.	Investigative	[37]
d-AP5	DMY5OTN	Discovery agent	N.A.	Investigative	[15]
D-aspartic acid	DM7Z892	Discovery agent	N.A.	Investigative	[15]
d-CCPene	DM36D0F	Discovery agent	N.A.	Investigative	[15]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[38]
DQP-1105	DMQLJ3Y	Discovery agent	N.A.	Investigative	[39]
Gly-Amp-Glu	DMO8LAC	Discovery agent	N.A.	Investigative	[20]
Gly-b7Pro-Glu	DM8L09J	Discovery agent	N.A.	Investigative	[20]
Gly-Hyp-Glu	DM8XR4Y	Discovery agent	N.A.	Investigative	[20]
Gly-Pip-Glu	DMM0JA4	Discovery agent	N.A.	Investigative	[20]
H-Gly-D-dmP-Glu-OH	DMX2TGD	Discovery agent	N.A.	Investigative	[40]
H-Gly-dmP-Glu-OH	DMOYQPM	Discovery agent	N.A.	Investigative	[40]
homoquinolinic acid	DMBW5DU	Discovery agent	N.A.	Investigative	[15]
L-aspartic acid	DMWGPO6	Hypokalemia	5C77	Investigative	[15]
LY233053	DMC82DA	Discovery agent	N.A.	Investigative	[15]
N,N'-Bis-(4-butoxy-phenyl)-guanidine	DMLOP2B	Discovery agent	N.A.	Investigative	[22]
N,N'-Bis-(4-butyl-phenyl)-guanidine	DMOS2GH	Discovery agent	N.A.	Investigative	[22]
N,N'-Bis-(4-ethyl-phenyl)-guanidine	DM0CTG7	Discovery agent	N.A.	Investigative	[22]
N,N'-Bis-(4-hexyl-phenyl)-guanidine	DM0RQGU	Discovery agent	N.A.	Investigative	[22]
N,N'-Bis-(4-isopropyl-phenyl)-guanidine	DMM38BC	Discovery agent	N.A.	Investigative	[22]
N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	DMFDXLB	Discovery agent	N.A.	Investigative	[22]
N-(2-methoxybenzyl)cinnamamidine	DM06S5Z	Discovery agent	N.A.	Investigative	[41]
N-(3-phenethoxybenzyl)-4-hydroxybenzamide	DMHZU8K	Discovery agent	N.A.	Investigative	[42]
N-(4-(benzyloxy)phenethyl)pyridin-4-amine	DMIPKNQ	Discovery agent	N.A.	Investigative	[43]
N1-dansyl-spermine	DM76CLF	Discovery agent	N.A.	Investigative	[15]
Nle-Pro-Glu	DM0FA6B	Discovery agent	N.A.	Investigative	[20]
NP93-31	DMMZXRT	Brain injury	NA07.Z	Investigative	[15]
NVP-AAM077	DM9DURZ	Discovery agent	N.A.	Investigative	[44]
Phe-Pro-Glu	DMJMLKA	Discovery agent	N.A.	Investigative	[20]
PHENCYCLIDINE	DMQBEYX	Discovery agent	N.A.	Investigative	[45]
Phenethyl-(3-phenyl-propyl)-amine	DMQWFO1	Discovery agent	N.A.	Investigative	[29]
Phenethyl-(4-phenyl-butyl)-amine	DMFQMHK	Discovery agent	N.A.	Investigative	[29]
Ro 63-1908	DMYVQF5	N. A.	N. A.	Investigative	[46]
RPR-118723	DMLDWCB	Discovery agent	N.A.	Investigative	[19]
Tenocyclidine	DMRM1QV	Discovery agent	N.A.	Investigative	[47]
TRANSTORINE	DMP4T87	Discovery agent	N.A.	Investigative	[28]
UBP141	DM6IG5J	Discovery agent	N.A.	Investigative	[21]
[3H]CGP39653	DMITR7A	Discovery agent	N.A.	Investigative	[15]
[3H]CGS19755	DM7H3JN	Discovery agent	N.A.	Investigative	[15]
[3H]CPP	DMR5UBF	Discovery agent	N.A.	Investigative	[15]
[3H]dizocilpine	DMEC2PF	Discovery agent	N.A.	Investigative	[15]
[3H]MDL105519	DMPKGHB	Discovery agent	N.A.	Investigative	[15]

References

• [1] NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
• [2] Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
• [3] NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
• [4] 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
• [5] Clinical pipeline report, company report or official report of Cadent Therapeutics.
• [6] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [9] Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
• [10] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [11] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [12] Clinical pipeline report, company report or official report of Evotec.
• [13] Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
• [14] Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
• [16] Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
• [17] CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018.
• [18] Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
• [19] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [20] New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
• [21] Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
• [22] Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
• [23] Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007 Mar 8;50(5):901-14.
• [24] NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
• [25] 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
• [26] Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
• [27] 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
• [28] 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
• [29] Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
• [30] Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24.
• [31] 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
• [32] 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
• [33] Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
• [34] Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6.
• [35] Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41.
• [36] Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13.
• [37] Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16.
• [38] Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52.
• [39] Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.
• [40] The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
• [41] Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41.
• [42] Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42.
• [43] Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19.
• [44] Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3.
• [45] Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52.
• [46] Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.
• [47] The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7.